Vertex Pharmaceuticals

VRTX is the ticker symbol for Vertex Pharmaceuticals, a company classified under the Biotechnology industry within the broader Health Care sector.

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Key metrics include a return on equity of 5.3%, a debt-to-equity ratio of 0.37.

The company reports trailing twelve-month revenue of $640.80M and net income of $1.03B.

FINOTAUR aggregates real-time and fundamental data on VRTX to help traders and investors make informed decisions. Track VRTX in your trading journal alongside other positions for a unified view of your portfolio.